Enzo Biochem, Inc. (ENZ) Misses Q1 Views
Enzo Biochem, Inc. (NYSE: ENZ) reported Q1 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $25.75 million versus the consensus estimate of $27.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c
- Paycom Software (PAYC) Tops Q4 EPS by 2c; Guides Q1 Above the Street
- RPX Corporation (RPXC) Tops Q4 EPS by 7c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!